AIM — AIM ImmunoTech Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 946644 ·
Last close
$0.19
Market Cap
$7.11M
52W High
$2.79
52W Low
$0.19
ADV30
8,705,363
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 22,000 | 18,000 | -2,226,000 | -3,023,000 | 8,585,000 | 5,816,000 | 6,460,000 |
| Dec 2025 | 21,000 | -19,000 | -2,952,000 | -4,175,000 | 5,782,000 | 2,985,000 | 15,565,000 |
| Sep 2025 | 26,000 | -42,000 | -2,447,000 | -3,284,000 | 5,494,000 | 2,347,000 | 11,571,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,315,000
Investing CF
$918,000
Financing CF
$15,315,000
CapEx
$-413,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.93
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-443,809,000
Inventory
—
Receivables
$0
ST Investments
$63,000
EBIT TTM
$-12,284,000
Pretax Income TTM
$-13,276,000
Interest Exp TTM
$992,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$95,000
EBITDA
$-10,734,000
Free Cash Flow
$-14,060,500
Enterprise Value
$706,022
Total Cash
$9,964,000
Total Debt
$3,921,000
Shares Out
37,429,420
Trailing EPS
$-0.71
Book Value
$0.27
ROE
-2382.3%
ROA
-82.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 88,000 | -11,664,000 | -13,958,000 | 5,782,000 | 15,565,000 | -9,783,000 | -10,957,000 |
| Dec 2024 | 170,000 | -19,772,000 | -17,320,000 | 8,608,000 | 9,930,000 | -1,322,000 | -14,888,000 |
| Dec 2023 | 202,000 | -31,916,000 | -28,962,000 | 19,381,000 | 9,147,000 | 10,234,000 | -21,267,000 |
| Dec 2022 | 141,000 | -19,923,000 | -19,445,000 | 40,488,000 | 2,020,000 | 38,468,000 | -16,108,000 |
TTM Snapshot
Revenues TTM
$120,000
NetIncome TTM
$-15,925,000
OpCashFlow TTM
$0
Assets (Latest)
$29,440,000
Forward EPS
$-0.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $6.79M | $1.03 | — |
| CUBT | Curative Biotechnology Inc | $8.89M | $1.00 | — |
| LIMN | Liminatus Pharma, Inc. | $5.63M | $4.20 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $10.25M | $0.33 | — |
| ZEOX | Zeo ScientifiX, Inc. | $10.66M | $1.36 | — |
News headlines (Yahoo Finance, 1h cache)
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
2026-09-22 12:55 · Yahoo
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
2026-09-09 13:03 · Yahoo
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
2026-08-27 13:01 · Yahoo
AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
2026-08-03 12:33 · Yahoo
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
2026-07-24 12:04 · Yahoo
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
2026-07-07 13:03 · Yahoo
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
2026-06-24 12:29 · Yahoo
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
2026-06-22 12:45 · Yahoo
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
2026-06-18 13:01 · Yahoo
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
2026-09-02 12:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.